Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Prescription Drug Advertising topic
No spam. Unsubscribe anytime.
Subcommittee hears bill to ban direct-to-consumer prescription drug ads; motion to table passes
Summary
House Bill 2131, sponsored by Delegate Milday, would remove a statutory exception that allows prescription drug advertising under the prohibition on practicing medicine without a license. The subcommittee heard testimony, then voted to table the bill 5–2.
House Bill 2131, introduced by Delegate Milday, would amend the statutory exception that currently allows advertising or sale of “commercial appliances or remedies” so that the exception “does not include prescription drugs or devices,” effectively prohibiting direct-to-consumer advertising of prescription medications in the Commonwealth.
The bill’s sponsor, Delegate Milday, told the subcommittee that manufacturers spend heavily on consumer advertising and “they’re not only manufacturing drugs, madam chair, they’re actually manufacturing demand for those drugs,” citing advertising dollars for products such as Dupixent and SKYRIZI as examples. Milday said the change closes a statutory loophole but acknowledged potential conflicts with federal regulation and enforcement by the Food and Drug Administration.
Supporters were not present in person and no online speakers appeared in favor. During questions, members raised the practical limits of a state ban when media markets cross state lines; Milday acknowledged that network broadcasts from outside Virginia could not practically be blocked and that federal law may preempt state rules.
After brief discussion the subcommittee considered motions. A motion to table House Bill 2131 was moved and seconded; the clerk opened the roll and the motion carried. The transcript records the bill as “tabled on a vote of 5 to 2.”
The bill’s sponsor and supporters framed the proposal as an attempt to reduce demand driven by advertising and to lower drug spending paid by consumers and public programs; opponents were not recorded in this hearing. The transcript shows the sponsor and members discussed federal preemption and media-market spillover as open legal and practical questions.
The subcommittee’s tabling means HB2131 will not advance from this hearing unless revived later in the session.
